<p>CSPC PHARMA (01093.HK) announced that the Group's developed chemical drug Class 1 new drug SYH2046 tablets have been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. The indication for this approved clinical trial is heart failure after acute myocardial infarction. The product was approved for clinical trials by the National Medical Products Administration of China in April of this year</p>

01093

<p>CSPC PHARMA announced that the Group's developed chemical drug Class 1 new drug SYH2046 tablets have been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. The indication for this approved clinical trial is heart failure after acute myocardial infarction. The product was approved for clinical trials by the National Medical Products Administration of China in April of this year</p>

CSPC PHARMA's new drug SYH2046 has been approved by the U.S. FDA to conduct clinical trials